2020年09月28日NanoString Technologies Inc.（NSTG）今日股票行情是多少？

　　截止2020年09月28日22时07分NanoString Technologies Inc.（NSTG）最新价43.9000，涨跌额0.2100，涨跌幅0.48%，昨收43.6900，今开44.6600，最高44.8400，最低43.6800，成交量17420手。

　　NanoString Technologies Inc.（NSTG）2020年01月01日至2020年03月31日Product and service金额（USD）2449.60万，比率92.07%。

　　报告日期2020年03月31日，年结日12-31，币种美元，NanoString Technologies Inc.（NSTG）收入2660.50万，收入增长-3.91%，毛利1558.80万，毛利增长-17.87%，归母净利润-3862.40万，归母净利润增长-76.38%，基本每股收益-1.04，稀释每股收益-1.04，销售毛利率58.59%，销售净利率-145.18%。

　　NanoString Technologies Inc.（NSTG）变动日期2020年05月05日，变动原因定期报告，已发行普通股3772.90万，已发行优先股--，公告日期2020年05月08日，已发行港股--，已发行国内股--，已发行海外股3772.90万，已发行其他股--。

　　NanoString Technologies Inc.（NSTG）主要指标（币种：美元）：截止2020年03月31日NanoString Technologies Inc.（NSTG）市盈率（TTM）-14.4067912701502，市净率（MRQ）9.14649047197596，每股收益（TTM）-1.52195947763675，每股净资产3.58170164833974，每股股息（USD）--，周息率--%，收入总额2660.50万，收入总额同比-3.91144177983242%，归母净利润-3862.40万，归母净利润同比-76.3814046944926%，毛利率58.5904905093028%，净利率-145.17571884984%，总股本3772.90万，总市值（USD）12.36亿。

　　NanoString Technologies Inc.（NSTG）2020年01月01日至2020年03月31日Americas金额（USD）0.20亿，比率73.67%。

　　公司介绍： NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

　　本站数据均为参考数据，不具备市场交易依据。